Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;11(12):685-6.
doi: 10.1038/nrclinonc.2014.190. Epub 2014 Nov 11.

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

Christopher A Klebanoff  1 , Tori N Yamamoto  1 , Nicholas P Restifo  1
Affiliations

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

Christopher A Klebanoff et al. Nat Rev Clin Oncol. 2014 Dec.

Abstract

Adoptive immunotherapy using T cells genetically engineered to express a chimeric antigen receptor that targets CD19, a B-cell differentiation antigen, has demonstrated impressive efficacy in a range of B-lymphoid malignancies. The latest results demonstrate the potential of this approach in patients with chemotherapy-refractory diffuse large B-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing interests.

Figures

Figure 1 |
Figure 1 |
Treatment of patients with B-cell malignancies using anti-CD19 CAR T cells. Patients with relapsed and/or refractory B-cell malignancies expressing the cell-surface protein CD19 can be treated successfully using adoptively transferred autologous T cells genetically engineered to express a CAR recognizing CD19. Abbreviation: CAR, chimeric antigen receptor.
See this image and copyright information in PMC

References

    1. Rosenberg SA et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011). - PMC - PubMed
    1. Kochenderfer JN et al. Chemotherapy- refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol 10.1200/JC0.2014.56.2025 (2014). - DOI - PMC - PubMed
    1. Kochenderfer JN et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010). - PMC - PubMed
    1. Kochenderfer JN et al. B-cell depletion and remissions of malignancy along with cytokine- associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012). - PMC - PubMed
    1. Porter DL, Levine BL, Kalos M, Bagg A & June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011). - PMC - PubMed